The production shortfall for cell therapies and viral vectors could have a devastating effect on the growth and success of the industry but what are the roots of the problem and who's going to solve it?
Cenk Sumen, Director at Thermo Fisher discuss durability of anticancer therapies and its importance in relation to pricing and reimbursement and providing a cure vs disease control
